Zydus Life Arm Inks Deal With Msn For Tablets To Treat Advanced Kidney Cancer

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Zydus Life Arm Inks Deal with MSN for Tablets to Treat Advanced Kidney Cancer

ri-calendar-2-lineMay 21, 2024

By: BlinkX Research Team

FbkFbkTwitterTelegram

Zydus Life's wholly owned subsidiary Zydus Lifesciences Global FZE on Friday entered into a significant licensing and supply agreement with MSN Laboratories for the Cabozantinib tablets to treat advanced kidney cancer, in the US.. 

 

Key Takeaways from the Agreement:

 

  • Zydus Life arm inked a licensing and supply agreement with MSN Laboratories for the US market for the Cabozantinib tablets to treat advanced kidney cancer.
  • MSN Lab will help manufacture and supply the generic version of the CABOMETYX drug.
  • Zydus Lifesciences Global FZE will distribute and sell the product in the US market.
  • The total addressable opportunity of cabozantinib tablets in the US is approximately $1,464 million.

 

Under the agreement, MSN Laboratories will manufacture and supply the generic version of the CABOMETYX drug while Zydus Lifesciences Global FZE will market, distribute and sell the product in the US market.

 

According to Zydus MD, Sharvil Patel, Cabozantinib is an important treatment option for many cancer patients and the company is pleased to work with MSN to bring the generic version of CABOMETYX to the US market.

 

Working with Zydus will enable the successful commercialisation of the tablet while advancing MSN's mission of enabling access to high-quality, affordable medicines, MSN Reddy, founder, chairman and MD of MSN Group said.

 

As per the IQVIA MAT 20254 data, the total addressable opportunity of cabozantinib tablets in the US is approximately $1,464 million.

 

About Zydus Lifesciences Limited:

 

Zydus Lifesciences Limited, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. Zydus has domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions,  from formulations to active pharmaceutical ingredients and animal healthcare products to wellness products.

 

Read More About Zydus Lifesciences Limited Share Price Here!

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions